Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Dec 10, 2012)
  • 8-K (Nov 15, 2012)
  • 8-K (Sep 6, 2012)
  • 8-K (Aug 31, 2012)
  • 8-K (Aug 29, 2012)
  • 8-K (Aug 6, 2012)

 
Other

HELICOS BIOSCIENCES CORP 8-K 2009

Documents found in this filing:

  1. 8-K
  2. Ex-4.1
  3. Ex-10.1
  4. Ex-10.2
  5. Ex-99.1
  6. Graphic
  7. Graphic

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): September 15, 2009

 


 

HELICOS BIOSCIENCES CORPORATION

(Exact Name of Registrant as Specified in Charter)

 


 

Delaware

 

001-33484

 

05-0587367

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

One Kendall Square
Building 700
Cambridge, Massachusetts

 

02139

(Address of Principal Executive Offices)

 

(Zip Code)

 

(617) 264-1800

(Registrant’s telephone number, including area code)

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 


 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 



 

Item 1.01.                                          Entry into a Material Definitive Agreement.

 

On September 15, 2009, Helicos BioSciences Corporation (“Helicos” or the “Company”) announced that it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors pursuant to which it has agreed to (i) sell to Atlas Ventures, Flagship Ventures, Highland Capital Partners and Versant Ventures, up to an aggregate of 1,030,028 units, each unit consisting of (A) one share of Common Stock and (B) one Warrant to purchase 0.662 shares of Common Stock at a per share exercise price equal to $2.61 (105% of the closing bid price of the Common Stock on September 15, 2009), each such unit to be at a purchase price equal to $2.57 per unit, and (ii) sell to certain new investors, up to an aggregate of 3,281,252 units, each unit consisting of (A) one share of Common Stock and (B) one Warrant to purchase 0.50 shares of Common Stock at a per share exercise price equal to $2.61, each such unit to be at a purchase price equal to $2.24 per unit (together, the “Offering”).

 

Units will not be issued or certificated.  The Shares and Warrants are immediately separable and will be issued separately.  The Warrants will have a five and a half year term and include a six-month “lock-up” provision, meaning that the Warrants will not be exercisable until six months following the consummation of the Offering. The closing of the transaction is expected to occur on or about September 18, 2009, subject to the satisfaction of customary closing conditions.

 

In connection with the Offering, the Company has entered into a registration rights agreement (the “Registration Rights Agreement”) with each of the investors.  The Registration Rights Agreement provides that the Company will file a “resale” registration statement (the “Initial Registration Statement”) covering all of the Shares and the shares issuable upon exercise of the Warrants (the “Warrant Shares”), up to the maximum number of shares able to be registered pursuant to applicable Securities and Exchange Commission (“SEC”) regulations, within 15 days of the closing of the Offering.  If any Shares or Warrant Shares are unable to be included on the Initial Registration Statement, the Company has agreed to file subsequent registration statements until all the Shares and Warrant Shares have been registered.  Under the terms of the Registration Rights Agreement, the Company is obligated to maintain the effectiveness of the “resale” registration statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions.  A cash penalty at the rate of 2% per month will be triggered for any filing or effectiveness failures or if, at any time after six months following the closing of the Offering, the Company ceases to be current in its periodic reports with the SEC. The aggregate penalty accrued with respect to each investor may not exceed 12% of the original purchase price paid by that investor.

 

The foregoing description of each of the Securities Purchase Agreement, the Registration Rights Agreement and the form of warrant is qualified in its entirety by reference thereto, which are filed as Exhibits 10.1, 10.2 and 4.1 to this Current Report, respectively, and are incorporated herein by reference.  The press release announcing the Offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

2



 

Item 3.02.                                          Unregistered Sales of Equity Securities.

 

The disclosure in Item 1.01 is incorporated herein by reference thereto.  The securities were offered pursuant to the exemptions from registration set forth in section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.

 

Item 9.01.              Financial Statements and Exhibits.

 

(d)           Exhibits

 

Exhibit No.

 

Description

 

 

 

 

4.1

 

 

Form of Warrant

 

 

 

 

10.1

 

 

Securities Purchase Agreement, between Helicos and each of the Purchasers identified therein, dated September 15, 2009

 

 

 

 

10.2

 

 

Registration Rights Agreement, between Helicos and each of the Holders identified there, dated September 15, 2009

 

 

 

 

99.1

 

 

Press Release, dated September 16, 2009

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HELICOS BIOSCIENCES CORPORATION

 

 

 

 

 

By:

/s/ Jeffrey R. Moore

Date: September 17, 2009

Name:

Jeffrey R. Moore

 

Title:

Senior Vice President & Chief Financial Officer

 

4



 

INDEX OF EXHIBITS

 

Exhibit No.

 

Description

 

 

 

 

4.1

 

 

Form of Warrant

 

 

 

 

10.1

 

 

Securities Purchase Agreement, between Helicos and each of the Purchasers identified therein, dated September 15, 2009

 

 

 

 

10.2

 

 

Registration Rights Agreement, between Helicos and each of the Holders identified there, dated September 15, 2009

 

 

 

 

99.1

 

 

Press Release, dated September 16, 2009

 

5


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki